September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
|Podcasts|June 28, 2022
Pharmacy Focus: Oncology Edition - What You Missed at ASCO 2022
This month, we reviewed key topics and interviews from the American Society of Clinical Oncology 2022 Annual Meeting.
Advertisement
This month, we reviewed key topics and interviews from the American Society of Clinical Oncology 2022 Annual Meeting. Experts discussed pharmacists' roles in clinical trial enrollment, CAR T therapies for multiple myeloma, new data from the ATHENA-MONO trial in ovarian cancer, and more.
Advertisement
Related to this article
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
4
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
5